alendronate has been researched along with Arthritis, Rheumatoid in 36 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 9.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| " The present study was undertaken to compare strength changes, measured using this newer method, in rheumatoid arthritis (RA) patients who were treated with alendronate (ALN) versus those who were not." | 9.13 | Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. ( Hamai, S; Hoffmann, PF; Iwamoto, Y; Keaveny, TM; Kinukawa, N; Mawatari, T; Miura, H; Nakashima, Y; Okazaki, K; Sakai, S; Shuto, T, 2008) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 9.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| "Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying diseases who receive chronic low-dose prednisone treatment." | 6.72 | Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. ( Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM, 2006) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 6.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| " The two groups were similar at baseline in underlying disease, age, duration of RA, duration of alendronate use, laboratory findings, and rheumatoid arthritis drugs." | 5.69 | Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial. ( Esmaily, H; Mehrnaz Aghili, S; Saeidi, S; Sahebari, M; Salari, M; Sarafraz Yazdi, M, 2023) |
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 5.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| " The present study was undertaken to compare strength changes, measured using this newer method, in rheumatoid arthritis (RA) patients who were treated with alendronate (ALN) versus those who were not." | 5.13 | Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. ( Hamai, S; Hoffmann, PF; Iwamoto, Y; Keaveny, TM; Kinukawa, N; Mawatari, T; Miura, H; Nakashima, Y; Okazaki, K; Sakai, S; Shuto, T, 2008) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 5.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| " We document one case of BRONJ associated with oral administration of methotrexate, a known immunosuppressive drug used to treat rheumatoid arthritis." | 3.80 | Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report. ( Adams, L; Alsalleeh, F; Bavitz, B; Keippel, J, 2014) |
| "We aimed to evaluate the clinical efficacy of monotherapy with alendronate and combined therapy with alendronate and menatetrenone (vitamin K2 [VitK2]) in postmenopausal rheumatoid arthritis (RA) patients with osteoporosis or osteopenia." | 3.79 | Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients. ( Fukushima, Y; Hamada, M; Nakase, T; Suzuki, K; Tomita, T; Tsuji, S; Yoshikawa, H, 2013) |
| "Clodronate (dichloromethylidene-bisphosphonate), a halogen-containing bisphosphonate, can inhibit the release of cytokines from RAW 264 macrophages and has anti-inflammatory properties in rheumatoid arthritis, whilst amino-containing bisphosphonates such as alendronate (4-amino-1-hydroxybutylidene-bisphosphonate), have pro-inflammatory properties and can cause an acute phase response." | 3.70 | Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. ( Azhayeva, E; Frith, JC; Makkonen, N; Mönkkönen, J; Rogers, MJ; Salminen, A; Urtti, A, 1999) |
| "Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying diseases who receive chronic low-dose prednisone treatment." | 2.72 | Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. ( Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM, 2006) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 2.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| " The manuscript then reviews therapies available for osteoporosis in the United States and makes recommendations about choosing therapies that minimize GI adverse effects in RA patients at high risk for such events." | 2.41 | Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. ( Schein, JR; Sewell, K, 2001) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| " Concerns have been raised about potential oversuppression of bone turnover and the development of atypical skeletal fragility associated with long-term use of bisphosphonates." | 1.36 | Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. ( Breglia, MD; Carter, JD, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 15 (41.67) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Sahebari, M | 1 |
| Sarafraz Yazdi, M | 1 |
| Mehrnaz Aghili, S | 1 |
| Esmaily, H | 1 |
| Saeidi, S | 1 |
| Salari, M | 1 |
| Xie, Z | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| Sun, X | 1 |
| Chen, S | 1 |
| Qin, A | 1 |
| Zhu, P | 1 |
| Zhang, J | 1 |
| Fan, S | 1 |
| Jensen, TW | 1 |
| Hansen, MS | 1 |
| Hørslev-Petersen, K | 1 |
| Hyldstrup, L | 1 |
| Abrahamsen, B | 1 |
| Langdahl, B | 1 |
| Zerahn, B | 1 |
| Pødenphant, J | 1 |
| Stengaard-Petersen, K | 1 |
| Junker, P | 1 |
| Østergaard, M | 1 |
| Lottenburger, T | 1 |
| Ellingsen, T | 1 |
| Andersen, LS | 1 |
| Hansen, I | 1 |
| Skjødt, H | 1 |
| Pedersen, JK | 1 |
| Lauridsen, UB | 1 |
| Svendsen, AJ | 1 |
| Tarp, U | 1 |
| Lindegaard, H | 1 |
| Jurik, AG | 1 |
| Vestergaard, A | 1 |
| Hetland, ML | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Muratore, M | 1 |
| Quarta, E | 1 |
| Quarta, L | 1 |
| Thompson, RN | 1 |
| Armstrong, CL | 1 |
| Heyburn, G | 1 |
| Krause, ML | 1 |
| Lehman, JS | 1 |
| Warrington, KJ | 1 |
| Alsalleeh, F | 1 |
| Keippel, J | 1 |
| Adams, L | 1 |
| Bavitz, B | 1 |
| Koh, JH | 1 |
| Myong, JP | 1 |
| Jung, SM | 1 |
| Lee, J | 1 |
| Kwok, SK | 1 |
| Park, SH | 1 |
| Ju, JH | 1 |
| Ebina, K | 1 |
| Noguchi, T | 1 |
| Hirao, M | 1 |
| Hashimoto, J | 1 |
| Kaneshiro, S | 1 |
| Yukioka, M | 1 |
| Yoshikawa, H | 2 |
| Lee, H | 1 |
| Bhang, SH | 1 |
| Lee, JH | 1 |
| Kim, H | 1 |
| Hahn, SK | 1 |
| Mawatari, T | 1 |
| Miura, H | 1 |
| Hamai, S | 1 |
| Shuto, T | 1 |
| Nakashima, Y | 1 |
| Okazaki, K | 1 |
| Kinukawa, N | 1 |
| Sakai, S | 1 |
| Hoffmann, PF | 1 |
| Iwamoto, Y | 1 |
| Keaveny, TM | 1 |
| Soejima, M | 1 |
| Kawaguchi, Y | 1 |
| Hara, M | 1 |
| Saito, S | 1 |
| Kamatani, N | 1 |
| Yamanaka, H | 1 |
| Somford, MP | 1 |
| Draijer, FW | 1 |
| Thomassen, BJ | 1 |
| Chavassieux, PM | 1 |
| Boivin, G | 1 |
| Papapoulos, SE | 1 |
| Lewiecki, EM | 1 |
| Breglia, MD | 1 |
| Carter, JD | 2 |
| Conte-Neto, N | 1 |
| Bastos, AS | 1 |
| Spolidorio, LC | 1 |
| Marcantonio, RA | 1 |
| Marcantonio, E | 1 |
| Bogado, CE | 1 |
| Boailchuk, JA | 1 |
| Zanchetta, MB | 1 |
| Massari, FE | 1 |
| Zanchetta, JR | 1 |
| Hoes, JN | 1 |
| Van der Goes, MC | 1 |
| Jacobs, JW | 1 |
| Lafeber, FP | 1 |
| Bijlsma, JW | 2 |
| Van Roon, JA | 1 |
| Mokuda, S | 1 |
| Okuda, Y | 1 |
| Onishi, M | 1 |
| Sawada, N | 1 |
| Matoba, K | 1 |
| Yamada, A | 1 |
| Jouyama, K | 1 |
| Takasugi, K | 1 |
| Curtin, BM | 1 |
| Fehring, TK | 1 |
| Suzuki, K | 1 |
| Tsuji, S | 1 |
| Fukushima, Y | 1 |
| Nakase, T | 1 |
| Hamada, M | 1 |
| Tomita, T | 1 |
| Tascioglu, F | 1 |
| Colak, O | 1 |
| Armagan, O | 1 |
| Alatas, O | 1 |
| Oner, C | 1 |
| Lems, WF | 1 |
| Lodder, MC | 1 |
| Lips, P | 1 |
| Geusens, P | 1 |
| Schrameijer, N | 1 |
| van de Ven, CM | 1 |
| Dijkmans, BA | 1 |
| Ornoy, A | 1 |
| Wajnberg, R | 1 |
| Diav-Citrin, O | 1 |
| Cruse, LM | 1 |
| Valeriano, J | 1 |
| Vasey, FB | 1 |
| Nakayama, H | 2 |
| Yamada, S | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Makkonen, N | 1 |
| Salminen, A | 1 |
| Rogers, MJ | 1 |
| Frith, JC | 1 |
| Urtti, A | 1 |
| Azhayeva, E | 1 |
| Mönkkönen, J | 1 |
| Konttinen, YT | 1 |
| Salo, T | 1 |
| Hanemaaijer, R | 1 |
| Valleala, H | 1 |
| Sorsa, T | 1 |
| Sutinen, M | 1 |
| Ceponis, A | 1 |
| Xu, JW | 1 |
| Santavirta, S | 1 |
| Teronen, O | 1 |
| López-Otín, C | 1 |
| Cantatore, FP | 1 |
| Acquista, CA | 1 |
| Pipitone, V | 1 |
| Sewell, K | 1 |
| Schein, JR | 1 |
| Yilmaz, L | 1 |
| Ozoran, K | 1 |
| Gündüz, OH | 1 |
| Uçan, H | 1 |
| Yücel, M | 1 |
| Gottlieb, S | 1 |
6 reviews available for alendronate and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Denosumab update.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone | 2009 |
Denosumab: an update.
Topics: Alendronate; Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromat | 2011 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteop | 2007 |
[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Topics: Alendronate; Apolipoprotein A-I; Arthritis, Rheumatoid; Atherosclerosis; Bone and Bones; Bone Densit | 2007 |
[Diagnosis, clinical feature and treatment of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteo | 2007 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Th | 2001 |
10 trials available for alendronate and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Humans; | 2023 |
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; | 2014 |
Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates.
Topics: Adrenal Cortex Hormones; Alendronate; Arthritis, Rheumatoid; Bone Density; Diphosphonates; Humans; T | 2013 |
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial.
Topics: Adult; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Compressive Stren | 2008 |
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Topics: Absorptiometry, Photon; Administration, Inhalation; Administration, Intranasal; Alendronate; Alkalin | 2005 |
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Analysis of Variance; Arthritis, Rheumato | 2006 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate.
Topics: Adult; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; beta 2-Microglobulin; Bone and Bone | 1999 |
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calc | 2001 |
Risk of ulcer soars with combination of arthritis drugs.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheuma | 2001 |
20 other studies available for alendronate and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.
Topics: Alendronate; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Bone Resorptio | 2018 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone Density Conservation Age | 2014 |
Multicentric reticulohistiocytosis can mimic rheumatoid arthritis.
Topics: Alendronate; Arthritis, Rheumatoid; Biopsy, Needle; Diagnosis, Differential; Drug Therapy, Combinati | 2014 |
Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.
Topics: Aged; Alendronate; Amoxicillin; Anti-Bacterial Agents; Apicoectomy; Arthritis, Rheumatoid; Bisphosph | 2014 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conserv | 2016 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarke | 2016 |
Tocilizumab-Alendronate Conjugate for Treatment of Rheumatoid Arthritis.
Topics: Alendronate; Animals; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone Density Conserv | 2017 |
Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection.
Topics: Adult; Alendronate; Arthritis, Rheumatoid; Atrophy; Bone and Bones; Bone Density Conservation Agents | 2008 |
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
Topics: Aged; Alendronate; Arthritis, Rheumatoid; Biopsy; Bone Density; Bone Density Conservation Agents; Ca | 2009 |
Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy.
Topics: Adrenal Cortex Hormones; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Diphosphonates; F | 2010 |
Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports.
Topics: Administration, Oral; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Di | 2011 |
Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis.
Topics: Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug | 2011 |
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Densit | 2012 |
Bisphosphonate fractures as a cause of painful total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bone D | 2011 |
Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Topics: Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Drug Thera | 2013 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation | 2006 |
Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.
Topics: Alendronate; Analgesics, Non-Narcotic; Animals; Arthritis, Rheumatoid; Cells, Cultured; Clodronic Ac | 1999 |
Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate.
Topics: Adult; Aged; Alendronate; Arthritis, Rheumatoid; Blotting, Western; Cartilage, Articular; Collagenas | 1999 |